Precision dosing Target small biotech niche with Veritope based assays to enable therapeutic drug monitoring for biologics, offering a differentiated value proposition in personalized medicine that aligns with Abreos' core technology.

Clinical partnerships Leverage past and ongoing collaborations (LifeAssays, ResearchDx) to propose joint development or co-marketing arrangements with CROs and diagnostic developers for companion tests and disease-monitoring panels.

MS and autoimmune focus Address opportunities in multiple sclerosis and autoimmune conditions where Tysabri and similar therapies require monitoring, proposing LDTs or standardized assays to support dose optimization and safety.

Diagnostic kit expansion Offer end-to-end diagnostic kit development and deployment services for biologic monitoring, including kit design, regulatory support, and scalable manufacturing to attract pharma and biotech customers seeking rapid deployment.

Market foothold Position as a nimble, specialized provider with proven track record and modest revenue base to target mid-market biotechs and contract labs, aiming for collaborations that scale with the growing need for personalized dosing analytics.